Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|December 1, 2006
Cunningham joins MacuSight board of directors
Union City, CA-MacuSight Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, announced the appointment of Brian C. Cunningham to its board of directors.
Advertisement
Union City, CA-MacuSight Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, announced the appointment of Brian C. Cunningham to its board of directors.
Cunningham presently serves as chief executive officer of DaoGen Inc. and Clerigen Inc., both early stage biopharmaceutical companies, and is of counsel to Cooley Godward Kronish LLP in its business department. In addition, Cunningham is a director of Synarc Inc., a private, imaging-based clinical research organization.
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
3
Diabetic macular edema: an inflammatory disease in focus
4
AAO 2026: GLP-1RA initiation not linked to anti-VEGF burden in DME
5